BRIEF published on 09/19/2024 at 23:10, 26 minutes ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 26 minutes ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 31 minutes ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 16 days 10 hours ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 16 days 10 hours ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 16 days 10 hours ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 22 days 10 hours ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
BRIEF published on 08/28/2024 at 13:05, 22 days 10 hours ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
PRESS RELEASE published on 08/28/2024 at 13:00, 22 days 10 hours ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 29 days 10 hours ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
Published on 09/19/2024 at 23:15, 21 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 36 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 20:15, 3 hours 21 minutes ago Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Published on 09/19/2024 at 21:09, 2 hours 26 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 4 hours 51 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 5 hours 33 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 5 hours 43 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 5 hours 43 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 5 hours 51 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 5 hours 51 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 5 hours 51 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)